refined the consensus classification of MIBC (30) and identified four robust integrative consensus subtypes (iCS1-iCS4) which had distinctive molecular patterns and were associated with stratified prognosis, different tumor immune microenvironment, and distinct sensitivity to immune checkpoint inhibitor therapy (111). This evidence concerns the gene DNAI1 and neoplasm.